Merck’s unlicensed Ebola vaccine shows 97.5% efficacy in Congo
Merck’s Ebola vaccine, which underwent phase-3 trial during the 2014-2015 Ebola epidemic in west Africa, has shown 97.5% efficacy in preventing Ebola disease when used during the current epidemic in…